Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Nobelpharma
Deal Size : $21.0 million
Deal Type : Series A Financing
Details : With this funding, VLPT aims to further accelerate the research and development of a cancer treatment vaccine as well as prophylactic vaccines including VLPM01, against malaria, dengue, etc. and move into clinical trials at the earliest date possible.
Brand Name : VLPM01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 27, 2021
Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Nobelpharma
Deal Size : $21.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
